See the published version of this preprint at BMC Pulmonary Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Keywords
Small-cell lung cancer, Osteopontin, biomarker, treatment responses, overall survival
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pulmonary Medicine.
Version 1
Posted 13 Jan, 2020
Community comments: 1
Editorial decision: Minor revision
On 04 Jun, 2020
Review #2 received
Received 17 Feb, 2020
Review #1 received
Received 17 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Reviewer #1 agreed
On 03 Feb, 2020
Editor assigned
On 27 Jan, 2020
Submission checks complete
On 10 Jan, 2020
Editor invited
On 10 Jan, 2020
First submitted
On 26 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Pulmonary Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pulmonary Medicine.
Version 1
Posted 13 Jan, 2020
Community comments: 1
Editorial decision: Minor revision
On 04 Jun, 2020
Review #2 received
Received 17 Feb, 2020
Review #1 received
Received 17 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Reviewer #1 agreed
On 03 Feb, 2020
Editor assigned
On 27 Jan, 2020
Submission checks complete
On 10 Jan, 2020
Editor invited
On 10 Jan, 2020
First submitted
On 26 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Pulmonary Medicine.
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Figure 1
Figure 2
Figure 3
Loading...